Alto Neuroscience (ANRO) Competitors $2.31 -0.11 (-4.36%) Closing price 03:59 PM EasternExtended Trading$2.34 +0.03 (+1.30%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. SEPN, CADL, DSGN, AVIR, ZYBT, CRVS, MBX, IMMP, PRME, and SLRNShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Septerna (SEPN), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Zhengye Biotechnology (ZYBT), Corvus Pharmaceuticals (CRVS), MBX Biosciences (MBX), Immutep (IMMP), Prime Medicine (PRME), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Septerna Candel Therapeutics Design Therapeutics Atea Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals MBX Biosciences Immutep Prime Medicine Acelyrin Septerna (NASDAQ:SEPN) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Do analysts prefer SEPN or ANRO? Septerna presently has a consensus price target of $33.00, suggesting a potential upside of 440.98%. Alto Neuroscience has a consensus price target of $16.75, suggesting a potential upside of 626.68%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is SEPN or ANRO more profitable? Septerna's return on equity of 0.00% beat Alto Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Alto Neuroscience N/A -49.28%-33.52% Which has stronger valuation & earnings, SEPN or ANRO? Septerna has higher revenue and earnings than Alto Neuroscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$981K276.10N/AN/AN/AAlto NeuroscienceN/AN/A-$36.31M-$2.54-0.91 Does the media refer more to SEPN or ANRO? In the previous week, Alto Neuroscience had 9 more articles in the media than Septerna. MarketBeat recorded 18 mentions for Alto Neuroscience and 9 mentions for Septerna. Alto Neuroscience's average media sentiment score of 0.79 beat Septerna's score of 0.14 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer SEPN or ANRO? Alto Neuroscience received 10 more outperform votes than Septerna when rated by MarketBeat users. Likewise, 83.33% of users gave Alto Neuroscience an outperform vote while only 71.43% of users gave Septerna an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes571.43% Underperform Votes228.57% Alto NeuroscienceOutperform Votes1583.33% Underperform Votes316.67% SummaryAlto Neuroscience beats Septerna on 5 of the 9 factors compared between the two stocks. Remove Ads Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeurosciencePharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$62.17M$6.91B$5.63B$19.37BDividend YieldN/A2.73%4.57%3.75%P/E Ratio-0.917.1723.3333.02Price / SalesN/A220.47388.4626.58Price / CashN/A65.6738.1617.54Price / BookN/A6.396.894.53Net Income-$36.31M$142.12M$3.20B$1.02B7 Day Performance-14.79%-5.18%-3.02%-1.27%1 Month Performance-17.68%-7.49%1.63%-4.01%1 Year Performance-85.02%-8.78%9.74%3.45% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience1.7455 of 5 stars$2.31-4.4%$16.75+626.7%-85.6%$62.17MN/A-0.91N/AGap DownSEPNSepterna2.0671 of 5 stars$6.37+7.6%$34.00+433.8%N/A$282.85M$981,000.000.00N/AEarnings ReportUpcoming EarningsAnalyst ForecastNews CoverageGap DownCADLCandel Therapeutics2.6634 of 5 stars$8.66+7.4%$21.00+142.5%+351.3%$281.24M$120,000.00-5.0160DSGNDesign Therapeutics1.9952 of 5 stars$4.93+6.0%$8.00+62.3%+7.2%$279.84MN/A-5.8040Gap UpAVIRAtea Pharmaceuticals2.6346 of 5 stars$3.20-0.6%$6.88+115.0%-24.5%$273.68MN/A-1.5570ZYBTZhengye BiotechnologyN/A$5.80+18.9%N/AN/A$273.56M$189.75M0.00278News CoverageHigh Trading VolumeCRVSCorvus Pharmaceuticals2.3073 of 5 stars$4.25-1.4%$12.38+191.2%+88.3%$273.09MN/A-4.5730Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMBXMBX Biosciences1.502 of 5 stars$8.13+3.0%$37.25+358.2%N/A$271.74MN/A0.0036Gap DownIMMPImmutep1.8544 of 5 stars$1.84-2.1%$8.50+362.0%-23.8%$267.83M$5.14M0.002,021PRMEPrime Medicine2.8498 of 5 stars$2.03+4.1%$13.38+558.9%-70.4%$266.26M$2.98M-0.99234Gap DownSLRNAcelyrin3.1473 of 5 stars$2.64-4.0%$9.60+263.6%-60.9%$265.87MN/A-1.07135 Remove Ads Related Companies and Tools Related Companies Septerna Competitors Candel Therapeutics Competitors Design Therapeutics Competitors Atea Pharmaceuticals Competitors Zhengye Biotechnology Competitors Corvus Pharmaceuticals Competitors MBX Biosciences Competitors Immutep Competitors Prime Medicine Competitors Acelyrin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredRevealed: The Chip Stock Redefining AI as We Know ItIn this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech fir...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
